3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER_GOV
1
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
40
Neoplasms
8
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Quality of Life
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 1
1
Hot Flashes
1
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Gynecomastia
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Breast Diseases
1
Breast Cancer Subjects
1
Breast Cancer Metastatic
1
Breast Cancer Female
1
Bone Density
1
Advanced Metastatic Breast Cancer
1
Advanced Cancer
1
Interventions
exemestane
4
entinostat
4
Fulvestrant
4
ribociclib
3
palbociclib
3
abemaciclib
3
Anastrozole
3
Trastuzumab
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
AZD9833
2
tucatinib
1
trastuzumab deruxtecan
1
taxane
1
pertuzumab
1
pembrolizumab
1
ipatasertib
1
figitumumab
1
elacestrant
1
dactolisib
1
atezolizumab
1
Watchful Waiting
1
Trabectedin
1
Tamoxifen
1
STX-478
1
RAD1901
1
Paclitaxel
1
Metformin
1
Lapatinib
1
Imlunestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Diseases
×
Tamoxifen
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled